Pages that link to "Q46407253"

The following pages link to Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models (Q46407253):

Displaying 31 items.

• The detection, treatment, and biology of epithelial ovarian cancer (Q21198791) (← links)
• Mucins in cancer: function, prognosis and therapy (Q24633765) (← links)
• Deciphering the molecular nature of ovarian cancer biomarker CA125 (Q27015008) (← links)
• Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity. (Q33641923) (← links)
• MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress (Q33713506) (← links)
• CA125 in ovarian cancer (Q33859857) (← links)
• Potential application of curcumin and its analogues in the treatment strategy of patients with primary epithelial ovarian cancer (Q34833628) (← links)
• HN125: A Novel Immunoadhesin Targeting MUC16 with Potential for Cancer Therapy (Q35001563) (← links)
• Transmembrane mucins as novel therapeutic targets (Q35632645) (← links)
• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways (Q35837949) (← links)
• Mechanisms and Targets Involved in Dissemination of Ovarian Cancer (Q36180735) (← links)
• Computational selection of antibody-drug conjugate targets for breast cancer. (Q36771856) (← links)
• Effective antitumor therapy based on a novel antibody-drug conjugate targeting the Tn carbohydrate antigen (Q37222147) (← links)
• Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. (Q37326840) (← links)
• Challenges in Developing Bioanalytical Assays for Characterization of Antibody–Drug Conjugates (Q37854644) (← links)
• Evolving Strategies for Target Selection for Antibody-Drug Conjugates (Q38920359) (← links)
• Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates. (Q38924311) (← links)
• Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models (Q39165132) (← links)
• Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. (Q39408093) (← links)
• Anti-CA19-9 Diabody as a PET Imaging Probe for Pancreas Cancer (Q39538634) (← links)
• An Antibody–Drug Conjugate Targeting the Endothelin B Receptor for the Treatment of Melanoma (Q39606303) (← links)
• Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125 (Q39658505) (← links)
• Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16). (Q39861947) (← links)
• Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. (Q39959127) (← links)
• Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology (Q44746659) (← links)
• Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats (Q46547092) (← links)
• Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. (Q47309343) (← links)
• Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer (Q51356061) (← links)
• Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer. (Q52715664) (← links)
• MUC16 as a novel target for cancer therapy (Q57172159) (← links)
• The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins (Q92614045) (← links)